Objective: Colorectal adenocarcinoma, the most common tumor that metastasizes to the ovary, is often difficult to distinguish from primary ovarian mucinous adenocarcinoma (POMA). Obtaining the correct diagnosis is difficult but crucial to treatment and prognosis. Methods: We evaluated the immunohistochemical (IHC) expression of cytokeratin 7 (CK7), cytokeratin 20 (CK20), CDX2, CEA, MUC2, MUC5AC and a-methylacyl-CoA racemase (AMACR) in 22 POMAs and 41 metastatic colorectal adenocarcinomas (MCAOs) involving ovaries. Results: MCAOs, in contrast with POMAs, were almost always negative for MUC5 (97.6%), often negative for CK7 (82.9%), focal or diffuse positive for CDX2 (73.2%), diffuse positive for CK20 (65.9%), focal or diffuse positive for MUC2 (51.2%), diffuse positive for CEA (41.5%) and negative for AMACR (41.5%). We therefore considered CK7 (2), CK20 (diffuse þ), CDX2 (þ) and MUC2 (þ) to be colonic markers and regarded cases with expression of more than two colonic markers as MCAO, those with no expression of colonic markers as POMA and those with expression of one colonic marker as indeterminate. Using CK7/CK20/CDX2/ MUC2, 82.5% of the cases were correctly classified, 6.3% were misclassified and 6.3% were indeterminate. Conclusion: CK7, CK20, CDX2 and MUC2 IHC staining is a useful adjunctive diagnostic tool to differentiate MCAOs from POMAs, in addition to clinical history and gross and microscopic findings.
INTRODUCTION
Tumors that metastasize to the ovary are common and 5 -30% of ovarian cancers are metastatic malignancies (1, 2) . The prevalences of metastatic ovarian tumors differ among different countries according to the incidence of various cancers therein (1) . In Korea, colorectal adenocarcinoma is one of the most common secondary cancers of the ovary (3) . A history of previous malignancy can be a useful clue for the diagnosis of a metastatic ovarian tumor. Colonic adenocarcinoma may mimic primary ovarian carcinoma, and colonic adenocarcinoma accounts for most misdiagnosed metastatic ovarian tumors (1 -5) . Because colorectal cancer is usually treated with 5-fluorouracil and ovarian cancer is usually treated with paclitaxel and a platinum agent (6 -8) , distinguishing between these two entities is fundamental to patient treatment. Immunohistochemistry (IHC) can be useful in this diagnosis; currently, CK7/CK20 is considered the standard panel for differentiation. However, the CK7/ CK20 panel has limitations, in that both primary ovarian mucinous adenocarcinomas (POMAs) and metastatic colorectal adenocarcinomas (MCAOs) are mostly CK20-positive, and a subset of POMAs are CK7-negative, whereas some MCAOs are CK7-positive (9) . In this study, we evaluated seven selected IHC markers that have been reported to distinguish POMAs from MCAOs and identified the best combination of IHC markers to be used in routine practice for the differential diagnosis of POMA and MCAO.
PATIENTS AND METHODS

PATIENTS AND TISSUE SAMPLES
We analyzed 22 cases of POMA and 41 cases of MCAO with mucinous differentiation involving ovary between January 1996 and July 2008 at Seoul St Mary's Hospital. Mucinous differentiation was defined by the presence of at least focal areas of intracytoplasmic mucin globules in the tumor cells. All slides were reviewed and reclassified according to the 2003 WHO guidelines. Borderline mucinous tumors and microinvasive mucinous adenocarcinomas were excluded.
The mean age of patients with primary mucinous adenocarcinoma was 42 years (range 13 -71). The mean age of patients with metastatic mucinous adenocarcinoma from colorectum was 47 years (range 23 -74). All but one case of primary mucinous adenocarcinomas were surgically staged. Stages included: Stage I in 13 cases, Stage II in 2 cases, Stage III in 5 cases and Stage IV in 1 case. Of the 22 patients with POMA, 19 patients were treated with surgery and adjuvant chemotherapy and 3 patients were treated with surgery only. Other clinicopathologic data regarding tumor size, laterality and follow-up data were reported in another study (3) .
TISSUE ARRAY
In order to construct the tissue microarray block, 3 mm core biopsies were taken from viable, morphologically representative areas of the paraffin-embedded tumor tissues and assembled on a recipient paraffin block. This was carried out using a precision instrument (Micro Digital Co., Gunpo-si, Gyeonggi-do, Korea). After construction, 4 mm sections were cut and histology was verified by hematoxylin-eosin staining.
IMMUNOHISTOCHEMISTRY
Four-micrometer sections of the paraffin-embedded tissue arrays were deparaffinized, rehydrated in a graded series of alcohol and microwave-treated for 10 min in a citrate buffer (pH 6.0). Endogenous peroxidase activity was blocked using 0.3% hydrogen peroxide. The tissue arrays were processed in an automatic IHC staining machine using the standard protocols (Lab Vision Autostainer, Lab Vision Co., Fremont, CA, USA) with DAKO ChemMate TM EnVision TM system (DAKO, Carpinteria, CA, USA). The following antibodies were used: cytokeratin 7 (CK7) (1:50, OV-TL 12/30, DAKO), cytokeratin 20 (CK20) (1:50, Ks20.8, DAKO), CEA (1:50, II-7, DAKO), CDX2 (1:100, CDX2-88, BioGenex, San Ramon, CA, USA), MUC2 (1:100, Ccp58, Novocastra, Newcastle, UK), MUC5AC (1:100, CLH2, Novocastra) and a-methylacyl-CoA racemase (AMACR) (1:100, rabbit polyclonal, Biocare Medical, Walnut Creek, CA, USA). The sections were visualized with 3-3 0 -diaminobenzidine and tissue arrays were counterstained with Mayer's hematoxylin.
CK7, CK20, CDX2, CEA, MUC2, MUC5AC and AMACR expression were classified based on the fraction of tumor cells showing positive cytoplasmic staining (negative, 1 -10%; focal positive, 11 -50%; and diffuse positive, 50%).
STATISTICAL METHODS
All statistical analyses were performed using SPSS version 15.0 (Systat, Chicago, IL, USA) for windows. A x 2 test was used to compare the IHC results of POMAs and MCAOs. Survival duration was defined as the time from surgery to death. Survival curves were plotted using the Kaplan and Meier method and statistical significance was determined by the log-rank test. A P value ,0.05 was considered significant.
RESULTS
IHC OF CK7, CK20, CDX2, CEA, MUC2, MUC5AC AND AMACR
The results of IHC staining for CK7, CK20, CDX2, CEA, MUC2, MUC5AC and AMACR are summarized in Table 1 . POMAs were always negative for MUC2 (100%), negative or focal positive for CK20 (90.9%) and CEA (95.5%), and often positive for CK7 (90.8%) and MUC5AC (50.0%) (Fig. 1 ). MCAOs were almost always negative for MUC5AC (97.6%), often negative for CK7 (82.9%), focal or diffuse positive for CDX2 (73.2%) and MUC2 (51.2%), diffuse positive for CK20 (75.6%) and diffuse positive for CEA (41.5%) (Fig. 2) . CK7-negative, CK20 diffuse positive, CDX2-positive, CEA diffuse positive, MUC2-positive, MUC5AC-negative and AMACR-positive were all statistically associated with MCAO (P ¼ 0.00, P ¼ 0.00, P ¼ 0.00, P ¼ 0.01, P ¼ 0.00, P ¼ 0.00 and P ¼ 0.04, respectively). We thus considered CK7-negative, CK20 diffuse positive, CDX2-positive, CEA diffuse positive, MUC2-positive, MUC5AC-negative and AMACR-positive as colonic markers. The sensitivity, specificity, positive predictive value and negative predictive value of these colonic markers are summarized in Table 2 . The sum of the sensitivity and the specificity of each colonic marker was obtained. The four colonic markers that showed the highest values (CK7, CDX2, CK20 and MUC2) were selected for further evaluation. CK7/CDX2 showed the best results, correctly identifying 71.4% of the cases. CK7/CK20 and CK20/CDX2 showed the second best results, correctly classifying 65.1% each. Among the three-marker combinations, CK20/CDX2/MUC2 gave the best results (82.5% of the cases correctly classified), whereas the CK7/CK20/CDX2 combination gave the second best result (81.0% of the cases were correctly classified). When the four-marker combination CK7/CK20/CDX2/MUC2 was used, 82.5% of the cases were correctly classified, 6.3% were misclassified and 6.3% were indeterminate. With all seven markers, 74.6% of the cases were correctly classified, 6.3% were misclassified and 19.0% were indeterminate (Table 3) .
SURVIVAL
The median length of follow-up was 13 months (range 1 -122 months). Within the observation period, 31 out of 63 patients (49.2%) died of cancer-related causes. The 5-year 210 CK7, CK20, CDX2 and MUC2 in ovary cancer survival rates for POMA and MCAO were 9.6% and 86.5%, respectively (Fig. 3 ).
DISCUSSION
One of the most common metastatic tumors involving the ovary is colorectal adenocarcinoma (10) . To correctly diagnose ovarian tumors, an integrated diagnostic approach combining clinical, radiological and histological findings is necessary. Pathologic features supporting a diagnosis of MCAO rather than primary ovarian tumors are bilaterality (70%), a nodular pattern of ovarian involvement, luminal necrotic debris, garland or cribriform growth pattern, focal segmental necrosis of glands, high degree of nuclear atypia and individual infiltration of glands (10) . MCAO may be very similar to POMA histologically, and distinguishing colorectal carcinoma from primary ovarian tumors can be very difficult. In the present study, 59.1% of the POMAs were Stage I and 86.5% of the POMA patients survived at a 5-year follow-up. In contrast, only 9.6% of the MCAO patients survived with 5-year follow-up (Fig. 1) . The high survival rate of POMA patients supports the finding that these cases were not metastatic lesions. We included pathologically typical cases of POMAs and clinically evident cases of MCAO in this study only to evaluate the power of IHC in discrimination.
There have been many reports that CK7, CK20, CDX2, CEA, MUC2, MUC5AC, AMACR and so on are useful markers to distinguish metastatic tumors from primary tumors (11 -22) . The combined expression of CK7/CK20 is the most widely used marker. Colorectal carcinomas are usually CK72/CK20þ, whereas ovarian carcinomas are usually CK7þ/CK202. However, these markers are not as valuable in differentiating MCAOs from POMAs because POMAs are usually CK20þ (typically with focal staining but may be diffuse); colonic carcinoma with mucinous Jpn J Clin Oncol 2010;40(3) 211 differentiation is often CK7þ and a small fraction of POMAs are CK72/CK20þ (11, 13, 14, 16, 22) . CDX2, a homeobox gene encoding an intestine-specific transcription factor, is highly sensitive and specific for intestinal carcinoma (9,17 -19) . Vang et al. evaluated CK7/CK20/CDX2 markers to distinguish gastrointestinal tumors from primary mucinous ovarian tumor. They concluded that no single marker was sufficient as a diagnostic, and that CDX2 should be assessed in the context of coordinate expression with CK7. The expression of CEA is more frequently and more diffusely positive in colorectal carcinomas than in POMA (20) . The mucin expression profile may also be useful, since mucin expression is relatively organ-specific (21) . MUC5AC are generally positive for primary ovarian mucinous tumor, and MUC2 is a typical marker for colonic carcinoma. However, there are also areas of overlapping, partly because primary mucinous tumors frequently exhibit intestinal metaplasia and express markers characteristic of gastric, intestinal and pancreatobiliary epithelial cells (21) . AMACR, or P504S, has been demonstrated to be overexpressed in prostate cancers, hepatocellular carcinomas, renal cell carcinomas and colorectal carcinomas (22 -24) , but none of the 49 ovarian cancers tested overexpressed AMACR (22, 24) . In this study, we found that MCAOs were almost always negative for MUC5AC (97.6%), often negative for CK7 (82.9%), focal or diffuse positive for CDX2 (73.2%), diffuse positive for CK20 (75.6%), focal or diffuse positive for MUC2 (51.2%) and diffuse positive for CEA (41.5%). In contrast, POMAs were almost always negative for MUC2 (100%), negative or only focal positive for CK20 (90.9%) and CEA (95.5%), and often positive for CK7 (90.8%) and MUC5AC (50.0%). We hypothesized that more colonic markers expressed more likely colonic carcinoma. We selected most reliable colonic markers (CK7-negative, CK20 diffuse positive, CDX2-positive and MUC2-positive) and considered cases with more than two colonic marker expressions to be MCAOs, those with no colonic marker expression to be POMAs and those with only one colonic marker expression to be 212 CK7, CK20, CDX2 and MUC2 in ovary cancer indeterminate. Applying this algorithm, 82.5% (55 out of 63) of the cases were correctly classified, 6.3% (4/63) were misclassified and 6.3% (4/63) were indeterminate.
In conclusion, CK7 and CK20 may be the best twomarker combination for distinguishing colonic carcinoma from primary ovarian mucinous tumor, but this panel leaves many equivocal cases. A follow-up step of staining CDX2 and MUC2 may be useful to better distinguish colonic carcinoma from POMA.
